|Day's Range||0.0500 - 0.0500|
NEW YORK, NY / ACCESSWIRE / November 18, 2019 / Kadmon Holdings, Inc. (KDMN) today announced the closing of its previously announced underwritten public offering of 29,900,000 shares of common stock for gross proceeds of $101.6 million, before deducting underwriting discounts and estimated offering expenses, which includes the full exercise of the underwriters' option to purchase additional shares. Kadmon intends to use the net proceeds from the offering for the clinical development of its lead product candidates, discovery, research and preclinical studies of its other product candidates, and other general corporate purposes. The securities described above were offered by Kadmon pursuant to a shelf registration statement on Form S-3 that was declared effective by the Securities and Exchange Commission (the "SEC") on September 24, 2019.
NEW YORK, NY / ACCESSWIRE / November 18, 2019 / Kadmon Holdings, Inc. (NYSE:KDMN) today announced that Harlan W. Waksal, M.D., President and Chief Executive Officer, will present at the following investor ...
The gross proceeds to Kadmon from the Offering, before deducting underwriting discounts and commissions and other estimated expenses payable by Kadmon, are expected to be $88.4 million. In addition, Kadmon has granted the underwriters in the Offering a 30-day option to purchase up to an additional 3,900,000 shares of Kadmon's common stock on the same terms and conditions as the shares offered in the Offering.
Kadmon also intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock offered in the public offering on the same terms and conditions. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering.
Shares of Kadmon Holdings are up about 10% after the New York-based biopharmaceutical company said its treatment for certain patients with chronic graft-versus-host disease met the primary endpoint in a trial. Chronic graft-versus-host disease is a rare condition that can occur after a transplant. Kadmon said it expects to file the experimental therapy with the U.S. Food and Drug Administration next year. Its stock is up 58.65% year-to-date, while the S&P 500 has gained 23%.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 11) ACADIA Pharmaceuticals Inc (NASDAQ: ACAD ) Agenus Inc ...
NEW YORK / ACCESSWIRE / November 11, 2019 / Kadmon Holdings, Inc. (KDMN) today announced positive topline results from the planned interim analysis of ROCKstar (KD025-213), the fully enrolled pivotal trial evaluating KD025 in patients with chronic graft-versus-host disease (cGVHD) who have received at least two prior lines of systemic therapy. The trial met the primary endpoint of Overall Response Rate (ORR) at the interim analysis, which was conducted as scheduled two months after completion of enrollment.
It was a rough fourth quarter for many hedge funds, which were naturally unable to overcome the big dip in the broad market, as the S&P 500 fell by about 4.8% during 2018 and average hedge fund losing about 1%. The Russell 2000, composed of smaller companies, performed even worse, trailing the S&P by more […]
NEW YORK, NY / ACCESSWIRE / November 7, 2019 / Kadmon Holdings, Inc. (NYSE:KDMN) today provided a business update and reported financial and operational results for the third quarter of 2019. "Following ...
NEW YORK, NY / ACCESSWIRE / November 7, 2019 / Kadmon Holdings, Inc. (KDMN) today announced a strategic partnership with BioNova Pharmaceuticals Ltd. (BioNova) to form a joint venture to exclusively develop and commercialize KD025 for the treatment of graft-versus-host disease (GVHD) in the People's Republic of China. KD025, Kadmon's lead product candidate, is a ROCK2 inhibitor in a pivotal clinical trial in the United States for the treatment of chronic graft-versus-host disease (cGVHD).
NEW YORK, NY / ACCESSWIRE / October 21, 2019 / Kadmon Holdings, Inc. (KDMN) today announced that the U.S. Food and Drug Administration (FDA) has approved CLOVIQUE™ (Trientine Hydrochloride Capsules, USP), a room-temperature stable, branded generic product. Trientine hydrochloride is used for the treatment of Wilson's disease in patients who are intolerant of penicillamine.
Harlan Waksal became the CEO of Kadmon Holdings, Inc. (NYSE:KDMN) in 2014. This report will, first, examine the CEO...
NEW YORK, NY / ACCESSWIRE / October 3, 2019 / Kadmon Holdings, Inc. (NYSE:KDMN) today announced that the Company has entered into a transaction to divest approximately 1.4 million shares of MeiraGTx Holdings ...
NEW YORK, NY / ACCESSWIRE / September 17, 2019 / Kadmon Holdings, Inc. (NYSE:KDMN) today announced that the U.S. Food and Drug Administration (FDA) has approved its generic Trientine Hydrochloride Capsules ...
NEW YORK, NY / ACCESSWIRE / August 30, 2019 / Kadmon Holdings, Inc. (KDMN) today announced the appointment of Gregory S. Moss, Esq. Mr. Moss will also serve as the Company’s Chief Compliance Officer. “Greg has been a key part of Kadmon’s senior management team for many years, including during our IPO.
Kadmon Holdings (KDMN) completes enrollment in the study of its pipeline candidate, KD025, for the treatment of chronic graft-versus-host disease (cGVHD).
NEW YORK, NY / ACCESSWIRE / August 13, 2019 / Kadmon Holdings, Inc. (KDMN) today announced that KD025-213, an open-label registration trial of KD025 for the treatment of chronic graft-versus-host disease (cGVHD), is fully enrolled. The study is being conducted at more than 30 clinical sites throughout the United States. The Company expects to disclose outcomes from a planned interim analysis before year end.
NEW YORK, NY / ACCESSWIRE / August 5, 2019 / Kadmon Holdings, Inc. (NYSE: KDMN) today provided a business update and reported financial and operational results for the second quarter of 2019. “We have ...
Kadmon Holdings (KDMN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Kadmon Holdings, Inc. (NYSE:KDMN) shareholders will doubtless be very grateful to see the share price up 50% in the...
Moleculin (MBRX) petitions for new patents to cover annamycin, currently being developed for treating patients with relapsed or refractory acute myeloid leukemia. Shares rise.